March 19, 2018 / 6:07 AM / 4 months ago

BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate Vla15

March 19 (Reuters) - VALNEVA SE:

* REG-VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15

* NO SAFETY CONCERNS ASSOCIATED WITH VLA15 IN ANY TREATMENT GROUP ENCOURAGING IMMUNOGENICITY WITH VLA15

* VLA15 IS IMMUNOGENIC IN ALL DOSES AND FORMULATIONS TESTED

* GOOD OSPA-SPECIFIC IGG ANTIBODY RESPONSES AGAINST ALL OSPA SEROTYPES

* STUDY MET ITS PRIMARY ENDPOINT: VACCINE CANDIDATE SHOWED A FAVOURABLE SAFETY PROFILE.

* PHASE II IS CURRENTLY EXPECTED TO COMMENCE IN THE SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below